BIO BIOTON S.A.

GPW · PL · Healthcare · Biotechnology · bioton.pl

3.880PLN+1.97%Mkt Cap: 82.74M $P/E: —1d ago

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; and oral diab…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap82.74M USD

Enterprise Value99.46M USD

Revenue (TTM)65.15M USD

Gross Profit23.25M USD

Net Income (TTM)859.31K USD

Revenue/Share3.00 PLN

Last Price3.880 PLN

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees—

CountryPL

SectorHealthcare

IndustryBiotechnology

ISINPLBIOTN00029

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA13.88

EV/Revenue1.53

P/S1.27

P/B0.56

EPS (TTM)-0.10

EPS (Forward)—

52W Range

3.43039% of range4.580

52W High4.580 PLN

52W Low3.430 PLN

Profitability

Gross Margin32.49%

Oper. Margin-14.57%

EBITDA Margin11.00%

Profit Margin1.20%

ROE0.57%

ROA0.44%

Growth

Revenue Growth-11.00%

Earnings Growth—

Cash Flow & Leverage

Operating CF5.73M USD

CapEx (TTM)3.31M USD

FCF Margin-4.53%

FCF Yield-3.56%

Net Debt16.72M USD

Net Debt/EBITDA2.33

Balance Sheet

Debt/Equity0.10

Current Ratio1.24

Quick Ratio0.36

Book Value/Sh6.75 PLN

Cash/Share0.01 PLN

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 PLN

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split1:100

Split DateJan 13, 2014

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.85.86M

Float38.80M

Insiders56.31%

Institutions0.28%

Technical

SMA 503.763 (+3.1%)

SMA 2003.998 (-3.0%)

Beta0.17

S&P 52W Chg14.58%

Avg Vol (30d)39.22K

Avg Vol (10d)44.69K

Technical Indicators

RSI (14)57.0

MACD0.0002

MACD Signal-0.0321

MACD Hist.+0.0322

BB Upper3.943 PLN

BB Middle3.683 PLN

BB Lower3.422 PLN

BB Width14.14%

ATR (14)0.1114 PLN

Vol Ratio (20d)0.42x